Middle East And Africa Antiviral Drugs Market
حجم السوق بالمليار دولار أمريكي
CAGR :
% 
 فترة التنبؤ |
2024 –2030 |
 حجم السوق (السنة الأساسية) |
|
 حجم السوق (سنة التنبؤ) |
USD 2,225.82 |
 CAGR |
% |
| Major Markets Players |
>سوق الأدوية المضادة للفيروسات في الشرق الأوسط وأفريقيا، حسب المؤشرات (الأنفلونزا، فيروس نقص المناعة البشرية (HIV)، فيروس التهاب الكبد سي (HCV)، الفيروس التنفسي المخلوي، فيروس الهربس البسيط، الفيروس المضخم للخلايا البشرية (HCMV)، فيروس الحماق النطاقي (VZV)، فيروس التهاب الكبد ب (HBV)، عدوى فيروس كورونا، وغيرها)، نوع المريض (طفل، بالغ، وشيخوخي)، المنتجات (عن طريق الفم، والموضعية، والحقن)، نوع الدواء (عام وعلامة تجارية)، المستخدم النهائي (المستشفيات، والعيادات، والرعاية الصحية المنزلية ، والمراكز المتخصصة، ومراكز العيادات الخارجية، وغيرها)، قناة التوزيع (صيدلية المستشفى، والصيدلية عبر الإنترنت، والصيدلية بالتجزئة) - اتجاهات الصناعة والتوقعات حتى عام 2030.
تحليل ورؤى حول سوق الأدوية المضادة للفيروسات في الشرق الأوسط وأفريقيا
لقد أدى الوعي المتزايد بالعدوى الفيروسية في الشرق الأوسط وأفريقيا إلى تعزيز الطلب على السوق. كما يساهم ارتفاع الإنفاق على الرعاية الصحية لتحسين الخدمات الصحية في نمو السوق. يركز اللاعبون الرئيسيون في السوق على إطلاق خدمات مختلفة والموافقات عليها خلال هذه الفترة الحاسمة. بالإضافة إلى ذلك، يساهم التقدم المحسن في تقنيات تطوير الأدوية أيضًا في زيادة الطلب على الأدوية المضادة للفيروسات.
من المتوقع أن ينمو سوق الأدوية المضادة للفيروسات في الشرق الأوسط وأفريقيا في العام المتوقع بسبب زيادة عدد اللاعبين في السوق وتوافر الخدمات المتقدمة. إلى جانب ذلك، يشارك المصنعون في النشاط التنموي لإطلاق خدمات جديدة في السوق. إن التطور المتزايد في مجال تطوير الأدوية يعزز نمو السوق. ومع ذلك، فإن الصعوبات مثل الافتقار إلى البروتوكولات الموحدة والافتقار إلى المهنيين المهرة قد تعيق نمو سوق الأدوية المضادة للفيروسات في الشرق الأوسط وأفريقيا في الفترة المتوقعة.
من المتوقع أن يؤدي زيادة الإنفاق على الرعاية الصحية وتطوير الأدوية إلى إتاحة فرص للسوق. ومع ذلك، فإن الاستخدام المتزايد للعلاجات البديلة قد يشكل تحديًا لنمو السوق. تحلل شركة Data Bridge Market Research أن سوق الأدوية المضادة للفيروسات في الشرق الأوسط وأفريقيا من المتوقع أن تصل قيمتها إلى 2225.82 مليون دولار أمريكي بحلول عام 2030، بمعدل نمو سنوي مركب قدره 2.9٪ خلال الفترة المتوقعة.
|
تقرير القياس |
تفاصيل |
|
فترة التنبؤ |
2023 إلى 2030 |
|
سنة الأساس |
2022 |
|
سنوات تاريخية |
2021 (قابلة للتخصيص حتى 2015-2020) |
|
وحدات كمية |
الإيرادات بالملايين، والحجم بالوحدات، والتسعير بالدولار الأمريكي |
|
القطاعات المغطاة |
Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus, Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) |
|
Countries Covered |
South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, and Rest of Middle East and Africa |
|
Market Players Covered |
Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Zydus Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Teva Pharmaceuticals USA, Inc., EMERGENT, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd., BioCryst Pharmaceuticals, Inc, and Hetero. among others |
Middle East and Africa Antiviral Drugs Market Definition
Antiviral drugs are medications used to treat viral infections by inhibiting the replication of viruses within host cells. These drugs target specific viruses or types of viruses and work by either preventing the virus from entering the host cell or by blocking key enzymes or proteins required for viral replication. Unlike antibiotics, which are used to treat bacterial infections, antiviral drugs are generally less effective, as viruses have a much simpler structure and rely on host cells to replicate. However, they can still be useful in treating some viral infections, such as influenza, herpes, and HIV.
Middle East and Africa Antiviral Drugs Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising prevalence of viral infections
Viral infections have steadily increased around the world during the past few decades. A virus that enters the body, exploits its cells for replication and spreads causes a viral infection. Viral infections can result in various symptoms, from minor to major, and in some instances, even life-threatening ones. Globalization is one of the main causes of the increase in viral infections. People travel and communicate with each other across boundaries, making the world more connected than ever. Viral transmission from one area to another has accelerated due to this enhanced connectedness.
Thus, the rising prevalence of viral infections is a complex issue with many contributing factors. Globalization, population density, climate change, and antibiotic resistance all influence the spread of viruses. Hence, it is expected to drive market growth.
- Advancements in new antiviral drug development
Antiviral treatments are prescribed to patients with viral infections. The creation of novel antiviral medications has made tremendous strides throughout time. These developments have lowered the disease burden, improved the treatment of viral infections, and saved lives. There is much development in the field of new antiviral drugs.
Thus, advancements in new antiviral drug development have improved the treatment of viral infections, reduced the disease burden, and are expected to drive market growth.
Restraint
- High cost of antiviral drugs
The high cost of antiviral drugs can have significant implications for patients and healthcare systems. Patients who cannot afford these medications may go without treatment or rely on inferior treatments, leading to worse health outcomes. In addition, the high cost of antiviral drugs can strain healthcare budgets, particularly in countries with limited resources.
Thus, the high cost of antiviral drugs is expected to restrain the Middle East and Africa antiviral drugs market.
Opportunity
-
Rising novel drug delivery systems
Research on antiviral medications has emphasized creating novel drug delivery mechanisms. Over conventional drug administration techniques, novel delivery systems have several benefits, such as improved bioavailability, tailored drug delivery, and fewer adverse effects.
Thus, developing novel drug delivery systems is an important area of research in antiviral drugs. Nanoparticle drug delivery systems, hydrogels, dendrimers, microneedles, and cell-penetrating peptides are some promising drug delivery systems that have been investigated for antiviral drugs. These delivery systems offer several advantages over traditional drug delivery methods and have the potential to improve the efficacy and safety of antiviral drugs and are expected to create an opportunity in the market's growth.
Challenge
- Patent expiration of antiviral drugs
The process of patent expiration results in the original developer or patent holder losing their exclusive right to produce and market a specific medicine. The patent expiration of antiviral medications may significantly impact the pharmaceutical business since it may invite competition from producers of generic medications.
Antiviral medications' patents expire at the end of the time in which their creator has the sole right to manufacture and market the medication. Following the expiration of a drug's patent, other producers can create and market generic versions. This may result in greater competition and lower consumer prices. HIV, hepatitis B and C, herpes, influenza, and other viral illnesses are all treated with antiviral medications. Antiviral medications' patents expire at different times depending on the drug and the nation. Drug patents are typically granted for 20 years from the date of filing. Other producers are free to create and market generic versions of medicine once its patent has expired. Because the producer does not have to spend as much on marketing, research and development, and clinical studies, generic medications are often more affordable than name-brand medications.
Thus, patent expiration of antiviral drugs can have significant implications for the availability, affordability, and accessibility of these important medications and is expected to act as a challenge to market growth.
Recent Developments
- In January 2023, Merck, known as MSD, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago Biosciences, Inc. (Nasdaq: IMGO), at a purchase price of USD 36.00 per share in cash, without interest and subject to deduction for any required tax withholding. The acquisition will help in the growth of the revenue.
- In April 2021, Zydus Pharmaceuticals, Inc. announced that it had received restricted emergency use approval from the Drug Controller General of India (DCGI) to use the antiviral drug Virafin for the treatment of moderate COVID-19 infections. This will help the company to increase its Middle East and Africa presence and reputation in other regions of the globe.
Middle East and Africa Antiviral Drugs Market Scope
The Middle East and Africa antiviral drugs market is segmented into six notable segments based on indication, patient type, products, drug type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Indication
- Influenza
- Human Immunodeficiency Virus (HIV)
- Hepatitis C Virus
- Herpes Simplex Virus
- Human Cytomegalovirus (HCMV)
- Varicella-Zoster Virus (VZV)
- Hepatitis B Virus
- Respiratory Syncytial Virus
- Coronavirus Infection
- Others
On the basis of indication, the Middle East and Africa antiviral drugs market is segmented into influenza, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus, herpes simplex virus, human cytomegalovirus (HCMV), varicella-zoster virus (VZV), hepatitis B virus (HBV), coronavirus infection, and others.
Patient Type
- Child
- Adult
- Geriatric
On the basis of patient type, the Middle East and Africa antiviral drugs market is segmented into child, adult, and geriatric.
PRODUCTS
- Oral
- Topical
- Parenteral
On the basis of products, the Middle East and Africa antiviral drugs market is segmented into oral, topical, and parenteral.
Drug Type
- Generic
- Branded
On the basis of drug type, the Middle East and Africa antiviral drugs market is segmented into generic and branded.
End User
- Hospital
- Clinics
- Home Healthcare
- Speciality Centers
- Ambulatory Centers
- Others
On the basis of end user, the Middle East and Africa antiviral drugs market is segmented into hospitals, clinics, home healthcare, specialty centers, ambulatory centers, and others.
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
On the basis of distribution channel, the Middle East and Africa antiviral drugs market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy.
Middle East and Africa Antiviral Drugs Market Regional Analysis/Insights
The Middle East and Africa antiviral drugs market is categorized into six notable segments based on indication, patient type, products, drug type, end user, and distribution channel.
The countries covered in this market report are South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, and Rest of Middle East and Africa.
In 2023, South Africa dominates the Middle East and Africa region due to the strong presence of key players and due to the increasing demand from emerging markets and expansion.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Antiviral Drugs Market Share Analysis
Middle East and Africa antiviral drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the Middle East and Africa antiviral drugs market.
بعض اللاعبين الرئيسيين العاملين في سوق الأدوية المضادة للفيروسات في الشرق الأوسط وأفريقيا هم Gilead Sciences، Inc.، F. Hoffmann-La Roche Ltd، GLAXOSMITHKLINE PLC، Abbvie، Merck & Co.، Inc.، Johnson & Johnson Services، Inc.، Bristol-Myers Squibb Company، Cipla Inc.، Aurobindo Pharma، Dr. Reddy's Laboratories Ltd.، Zydus Pharmaceuticals، Inc.، Mylan Pharmaceuticals ULC، Teva Pharmaceuticals USA، Inc.، EMERGENT، Sun Pharmaceutical Industries Ltd.، Avet Pharmaceuticals Inc.، Pfizer Inc.، SIGA Technologies، NAVINTA LLC.، Macleods Pharmaceuticals Ltd.، BioCryst Pharmaceuticals، Inc، و Hetero وغيرها.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET
7 REGULATORY FRAMEWORK
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS
8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT
8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES
8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES
8.2 RESTRAINS
8.2.1 HIGH COST OF ANTIVIRAL DRUGS
8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES
8.3 OPPORTUNITIES
8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS
8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS
8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES
8.4 CHALLENGES
8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS
8.4.2 DEMAND FOR ALTERNATIVE MEDICINES
9 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION
9.1 OVERVIEW
9.2 INFLUENZA
9.2.1 NEURAMINIDASE INHIBITORS
9.2.1.1 OSELTAMIVIR
9.2.1.2 ZANAMIVIR
9.2.1.3 PERAMIVIR
9.2.1.4 LANINAMIVIR
9.2.2 M2 INHIBITORS
9.2.2.1 RIMANTADINE
9.2.2.2 OTHERS
9.2.3 RNA POLYMERASE INHIBITORS
9.2.3.1 FAVIPIRAVIR
9.2.3.2 BALOXAVIR MARBOXIL
9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV)
9.3.1 REVERSE TRANSCRIPTASE INHIBITORS
9.3.1.1 NUCLEOSIDE (NRTIS)
9.3.1.1.1 LAMIVUDINE
9.3.1.1.2 ABACAVIR
9.3.1.1.3 DIDANOSINE
9.3.1.1.4 OTHERS
9.3.1.2 NONNUCLEOSIDE (NNRTIS)
9.3.1.2.1 EFAVIRENZ
9.3.1.2.2 NEVIRAPINE
9.3.1.2.3 DELAVIRDINE
9.3.1.2.4 OTHERS
9.3.1.3 INTEGRASE
9.3.1.3.1 DOLUTEGRAVIR
9.3.1.3.2 ELVITEGRAVIR
9.3.1.3.3 RALTEGRAVIR
9.3.1.3.4 BICTEGRAVIR
9.3.1.4 NUCLEOTIDE
9.3.1.4.1 TENOFOVIR
9.3.1.4.2 OTHERS
9.3.1.5 INTERFERONS
9.3.1.5.1 ALPHA
9.3.1.5.2 BETA
9.3.1.5.3 GAMMA
9.3.1.6 GP41
9.3.1.6.1 ENFUVIRTIDE
9.3.1.6.2 OTHERS
9.3.2 PROTEASE
9.3.2.1 ATAZANAVIR
9.3.2.2 DARUNAVIR
9.3.2.3 LOPINAVIR
9.3.2.4 RITONAVIR
9.3.2.5 SAQUINAVIR
9.3.2.6 INDINAVIR
9.3.2.7 NELFINAVIR
9.3.2.8 TIPRANAVIR
9.3.2.9 AMPRENAVIR
9.4 HEPATITIS C VIRUS
9.4.1 NS5B POLYMERASE
9.4.1.1 SOFOSBUVIR
9.4.1.2 DASABUVIR
9.4.2 NS3/4A PROTEASE
9.4.2.1 DANOPREVIR
9.4.2.2 GLECAPREVIR
9.4.2.3 GRAZOPREVIR
9.4.2.4 PARITAPREVIR
9.4.2.5 SIMEPREVIR
9.4.3 NS5A PHOSPHOPROTEIN
9.4.3.1 LEDIPASVIR
9.4.3.2 VELPATASVIR
9.4.3.3 OMBITASVIR
9.4.3.4 ELBASVIR
9.4.3.5 DACLATASVIR
9.4.3.6 PIBRENTASVIR
9.4.4 NEURAMINIDASE
9.4.4.1 OSELTAMIVIR
9.4.4.2 ZANAMIVIR
9.4.4.3 PERAMIVIR
9.4.4.4 LANINAMIVIR
9.4.5 RNA POLYMERASE
9.4.5.1 BALOXAVIR MARBOXIL
9.4.5.2 FAVIPIRAVIR
9.4.6 MATRIX PROTEIN 2
9.4.6.1 RIMATIDINE
9.4.6.2 FAVIPIRAVIR
9.5 HERPES SIMPLEX VIRUS
9.5.1 DNA POLYMERASE UL30
9.5.1.1 ACICLOVIR
9.5.1.2 FAMCICLOVIR
9.5.1.3 VALACICLOVIR
9.5.1.4 PENCICLOVIR TRIFLURIDINE
9.5.1.5 BRIVUDINE
9.5.1.6 FOSCARNET
9.5.1.7 IDOXURIDINE
9.5.2 ENVELOPE PROTEINS
9.5.2.1 DOCOSANOL
9.5.2.2 OTHERS
9.6 HUMAN CYTOMEGALOVIRUS (HCMV)
9.6.1 GANCICLOVIR
9.6.2 VALGANCICLOVIR
9.6.3 CIDOFOVIR
9.6.4 FOSCARNET
9.6.5 FOMIVIRSEN
9.7 VARICELLA-ZOSTER VIRUS (VZV)
9.7.1 VALACICLOVIR
9.7.2 FAMCICLOVIR
9.7.3 ACICLOVIR
9.7.4 VIDARABINE
9.7.5 BRIVUDINE
9.8 HEPATITIS B VIRUS
9.8.1 ENTECAVIR
9.8.2 TENOFOVIR
9.8.3 TELBIVUDINE
9.8.4 TENOFOVIR ALAFENAMIDE
9.8.5 OTHERS
9.9 RESPIRATORY SYNCYTIAL VIRUS
9.9.1 RNA POLYMERASE
9.9.1.1 RIBAVIRIN
9.9.1.2 OTHERS
9.9.2 FUSION GLYCOPROTEIN
9.9.2.1 PALIVIZUMAB
9.9.2.2 OTHERS
9.1 CORONAVIRUS INFECTION
9.11 OTHERS
10 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 GERIATRIC
10.2.1 MALE
10.2.2 FEMALE
10.3 CHILD
10.3.1 MALE
10.3.2 FEMALE
10.4 ADULT
10.4.1 MALE
10.4.2 FEMALE
11 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS
11.1 OVERVIEW
11.2 ORAL
11.2.1 SOLID
11.2.1.1 TABLETS
11.2.1.2 CAPSULES
11.2.1.3 OTHERS
11.2.2 SEMISOLID
11.2.2.1 GELS
11.2.2.2 EMULSIONS
11.2.2.3 ELIXIRS
11.2.2.4 OTHERS
11.2.3 LIQUID
11.2.3.1 SOLUTIONS
11.2.3.2 SYRUPS
11.2.3.3 OTHERS
11.3 TOPICAL
11.3.1 SEMI-SOLID
11.3.1.1 CREAM
11.3.1.2 OINTMENT
11.3.1.3 GELS
11.3.1.4 OTHERS
11.3.2 LIQUID
11.3.2.1 SOLUTIONS
11.3.2.2 SUSPENSIONS
11.3.3 SOLID
11.3.3.1 POWDERS
11.3.3.2 SUPPOSITORIES
11.3.3.3 ENEMA
11.3.3.4 OTHERS
11.4 PARENTERAL
11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS
11.4.1.1 SOLUTIONS
11.4.1.2 RECONSTITUTED/LYOPHILIZED
11.4.1.3 SUSPENSIONS
11.4.1.4 EMULSIONS
11.4.1.5 OTHERS
11.4.2 NOVEL DRUG DELIVERY FORMULATIONS
11.4.3 COLLOIDAL DISPERSIONS
11.4.4 LONG ACTING INJECTION FORMULATION
12 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERIC
12.3 BRANDED
13 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 SPECIALTY CENTERS
13.4 AMBULATORY CENTRES
13.5 CLINICS
13.6 HOME HEALTHCARE
13.7 OTHERS
14 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY REGION
15.1 MIDDLE EAST AND AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 UAE
15.1.4 EGYPT
15.1.5 KUWAIT
15.1.6 ISRAEL
15.1.7 REST OF MIDDLE EAST AND AFRICA
16 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 GILEAD SCIENCES, INC. (2022)
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 PFIZER INC. (2022)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 SIGA TECHNOLOGIES (2022)
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 GLAXOSMITHKLINE PLC.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 F. HOFFMANN-LA ROCHE LTD. (2022)
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 ABBVIE INC.
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 AUROBINDO PHARMA (2022)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 AVET PHARMACEUTICALS INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 BRISTOLL MYERS SQUIBB (2022)
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 BIOCRYST PHARMACEUTICALS, INC. (2022)
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENT
18.11 CIPLA INC. (2022)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 DR. REDDY’S LABORATORIES LTD. (2022)
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 EMERGENT (2022)
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENT
18.14 HETERO.
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 MACLEODS PHARMACEUTICALS LTD.
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 MERCK & CO., INC, (2022)
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022)
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 NAVINTA LLC.
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022)
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022)
18.21.1 COMPANY SNAPSHOT
18.21.2 REVENUE ANALYSIS
18.21.3 PRODUCT PORTFOLIO
18.21.4 RECENT DEVELOPMENT
18.22 ZYDUS PHARMACEUTICALS, INC. (2022)
18.22.1 COMPANY SNAPSHOT
18.22.2 REVENUE ANALYSIS
18.22.3 PRODUCT PORTFOLIO
18.22.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021- 2030 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA HUMAN CYTOMEGALOVIRUS (HCMV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA HEPATITIS B VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTIAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA CORONAVIRUS INFECTION IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021- 2030 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCT, 2021- 2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021- 2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021- 2030 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 81 MIDDLE EAST AND AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 82 MIDDLE EAST AND AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 83 MIDDLE EAST AND AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 84 MIDDLE EAST AND AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 85 MIDDLE EAST AND AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 86 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 87 MIDDLE EAST AND AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 88 MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 MIDDLE EAST AND AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 90 MIDDLE EAST AND AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 91 MIDDLE EAST AND AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 92 MIDDLE EAST AND AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 93 MIDDLE EAST AND AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 94 MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 95 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 96 MIDDLE EAST AND AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 97 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 98 MIDDLE EAST AND AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 99 MIDDLE EAST AND AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 100 MIDDLE EAST AND AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 101 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 102 MIDDLE EAST AND AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 103 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 104 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 105 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 106 MIDDLE EAST AND AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 107 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 108 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 109 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 110 MIDDLE EAST AND AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 111 MIDDLE EAST AND AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 112 MIDDLE EAST AND AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 113 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 114 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 117 SOUTH AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 118 SOUTH AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 SOUTH AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 120 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 121 SOUTH AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 122 SOUTH AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 123 SOUTH AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 124 SOUTH AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 125 SOUTH AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 126 SOUTH AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 127 SOUTH AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 128 SOUTH AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 129 SOUTH AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 130 SOUTH AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 131 SOUTH AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 132 SOUTH AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 133 SOUTH AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 134 SOUTH AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 135 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 136 SOUTH AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 137 SOUTH AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 138 SOUTH AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 139 SOUTH AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 140 SOUTH AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 141 SOUTH AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 142 SOUTH AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 143 SOUTH AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 144 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 145 SOUTH AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 146 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 147 SOUTH AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 148 SOUTH AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 149 SOUTH AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 150 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 151 SOUTH AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 152 SOUTH AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 153 SOUTH AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 154 SOUTH AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 155 SOUTH AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 156 SOUTH AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 157 SOUTH AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 158 SOUTH AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 159 SOUTH AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 160 SOUTH AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 161 SOUTH AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 162 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 163 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 164 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 165 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 166 SAUDI ARABIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 167 SAUDI ARABIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 168 SAUDI ARABIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 169 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 170 SAUDI ARABIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 171 SAUDI ARABIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 172 SAUDI ARABIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 173 SAUDI ARABIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 174 SAUDI ARABIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 175 SAUDI ARABIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 176 SAUDI ARABIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 177 SAUDI ARABIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 178 SAUDI ARABIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 SAUDI ARABIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 SAUDI ARABIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 181 SAUDI ARABIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 182 SAUDI ARABIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 183 SAUDI ARABIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 184 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 185 SAUDI ARABIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 186 SAUDI ARABIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 187 SAUDI ARABIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 188 SAUDI ARABIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 189 SAUDI ARABIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 190 SAUDI ARABIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 191 SAUDI ARABIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 192 SAUDI ARABIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 193 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 194 SAUDI ARABIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 195 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 196 SAUDI ARABIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 197 SAUDI ARABIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 198 SAUDI ARABIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 199 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 200 SAUDI ARABIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 201 SAUDI ARABIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 202 SAUDI ARABIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 203 SAUDI ARABIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 204 SAUDI ARABIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 205 SAUDI ARABIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 206 SAUDI ARABIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 207 SAUDI ARABIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 208 SAUDI ARABIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 209 SAUDI ARABIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 210 SAUDI ARABIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 211 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 212 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 213 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 214 U.A.E ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 215 U.A.E INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 216 U.A.E NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 217 U.A.E M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 218 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 219 U.A.E HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 220 U.A.E REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 221 U.A.E NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 222 U.A.E NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 223 U.A.E INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 224 U.A.E NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 225 U.A.E INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 226 U.A.E GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 227 U.A.E PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 228 U.A.E HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 229 U.A.E NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 230 U.A.E NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 231 U.A.E NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 232 U.A.E NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 233 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 234 U.A.E MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 235 U.A.E HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 236 U.A.E DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 237 U.A.E ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 238 U.A.E HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 239 U.A.E VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 U.A.E DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 241 U.A.E RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 242 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 243 U.A.E FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 244 U.A.E ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 245 U.A.E GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 246 U.A.E CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 247 U.A.E ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 248 U.A.E ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 249 U.A.E ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 250 U.A.E SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 251 U.A.E SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 252 U.A.E LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 253 U.A.E TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 254 U.A.E SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 255 U.A.E LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 256 U.A.E SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 257 U.A.E PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 258 UAECONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 259 U.A.E NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 260 U.A.E ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 261 U.A.E ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 262 U.A.E ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 263 EGYPT ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 264 EGYPT INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 265 EGYPT NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 266 EGYPT M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 267 EGYPT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 EGYPT HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 269 EGYPT REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 270 EGYPT NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 271 EGYPT NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 272 EGYPT INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 273 EGYPT NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 274 EGYPT INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 275 EGYPT GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 276 EGYPT PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 277 EGYPT HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 278 EGYPT NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 279 EGYPT NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 280 EGYPT NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 281 EGYPT MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 282 EGYPT HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 283 EGYPT DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 284 EGYPT ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 285 EGYPT HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 286 EGYPT VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 287 EGYPT DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 288 EGYPT RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 289 EGYPT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 290 EGYPT FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 291 EGYPT ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 292 EGYPT GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 293 EGYPT CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 294 EGYPT ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 295 EGYPT ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 296 EGYPT ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 297 EGYPT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 298 EGYPT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 299 EGYPT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 300 EGYPT TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 301 EGYPT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 302 EGYPT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 303 EGYPT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 304 EGYPT PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 305 EGYPT CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 306 EGYPT NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 307 EGYPT ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 308 EGYPT ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 309 EGYPT ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 310 KUWAIT ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 311 KUWAIT INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 312 KUWAIT NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 313 KUWAIT M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 314 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 315 KUWAIT HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 316 KUWAIT REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 317 KUWAIT NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 318 KUWAIT NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 319 KUWAIT INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 320 KUWAIT NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 321 KUWAIT INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 322 KUWAIT GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 323 KUWAIT PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 324 KUWAIT HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 325 KUWAIT NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 326 KUWAIT NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 327 KUWAIT NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 328 KUWAIT NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 330 KUWAIT MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 331 KUWAIT HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 332 KUWAIT DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 333 KUWAIT ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 334 KUWAIT HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 335 KUWAIT VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 336 KUWAIT DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 337 KUWAIT RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 338 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 339 KUWAIT FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 340 KUWAIT ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 341 KUWAIT GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 342 KUWAIT CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 343 KUWAIT ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 344 KUWAIT ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 345 KUWAIT ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 346 KUWAIT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 347 KUWAIT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 348 KUWAIT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 349 KUWAIT TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 350 KUWAIT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 351 KUWAIT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 352 KUWAIT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 353 KUWAIT PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 354 KUWAIT CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 355 KUWAIT NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 356 KUWAIT ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 357 ISRAEL ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 358 ISRAEL INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 359 ISRAEL NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 360 ISRAEL M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 361 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 362 ISRAEL HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 363 ISRAEL REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 364 ISRAEL NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 365 ISRAEL NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 366 ISRAEL INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 367 ISRAEL NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 368 ISRAEL INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 369 ISRAEL GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 370 ISRAEL PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 371 ISRAEL HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 372 ISRAEL NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 373 ISRAEL NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 374 ISRAEL NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 375 ISRAEL NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 376 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 377 ISRAEL MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 378 ISRAEL HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 379 ISRAEL DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 380 ISRAEL ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 381 ISRAEL HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 382 ISRAEL VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 383 ISRAEL DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 384 ISRAEL RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 385 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 386 ISRAEL FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 387 ISRAEL ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 388 ISRAEL GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 389 ISRAEL CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 390 ISRAEL ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 391 ISRAEL ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 392 ISRAEL ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 393 ISRAEL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 394 ISRAEL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 395 ISRAEL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 396 ISRAEL TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 397 ISRAEL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 398 ISRAEL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 399 ISRAEL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 400 ISRAEL PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 401 ISRAEL CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 402 ISRAEL NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 403 ISRAEL ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 404 ISRAEL ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 405 ISRAEL ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 406 REST OF MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: SEGMENTATION
FIGURE 11 THE RISING PREVALENCE OF VIRAL INFECTIONS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET IN THE FORECAST PERIOD
FIGURE 12 THE INFLUENZA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET
FIGURE 14 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY INDICATION , 2022
FIGURE 15 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY INDICATION , 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY INDICATION , CAGR (2023-2030)
FIGURE 17 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY INDICATION , LIFELINE CURVE
FIGURE 18 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, 2022
FIGURE 19 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PRODUCT, 2022
FIGURE 23 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, 2022
FIGURE 27 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY END USER, 2022
FIGURE 31 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: SNAPSHOT (2022)
FIGURE 39 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY COUNTRY (2022)
FIGURE 40 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: INDICATION (2023-2030)
FIGURE 43 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: COMPANY SHARE 2022 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
